Table 2.

Endogenous values of SPMs in various human tissues and organs.

Resolvins	Quantities in Tissue/Organ
Resolvin E1 (RvE1)	Plasma: 2–22 pg/mL [169] Stenotic Aortic Valves: 500–3500 pg/g tissue [149] Metabolic Syndrome (weight loss program): 1339 ± 175 pg/mL [150] Nonobstructive coronary artery disease (WARRIOR Trial) [151] Human Vagus Nerve: 19.7 ± 12.6 pg/tissue [152] COVID-19 and lung severity: Severe: 112.6 pg/mL [161] Obesity (adiposity): Men: 6.5 pg/mL [168] Women: 5.2 pg/mL [168] Salivary levels in Periodontal and cardiovascular therapies: 0-6 months: 1.11–1.24 pg/mL [170] Pregnancy: First Trimester: 0.0049 ± 0.036 [171] Second Trimester: 0.048 ± 0.037 [171] Third Trimester: 0.024 ± 0.027 [171] Anetholea anisita extract for scalp condition [172]
Resolvin E2 (RvE2)	Obesity (adiposity): Men: 10.7 pg/mL [168] Women: 11.4 pg/mL [168]
Resolvin E3 (RvE3)	Metabolic Syndrome (weight loss program): 175 ± 44 pg/mL [150] Obesity (adiposity): Men: 19.2 pg/mL [168] Women: 15.9 pg/mL [168]
Resolvin D1 (RvD1)	Nonobstructive coronary artery disease (WARRIOR Trial) [151] Plasma: 2–22 pg/mL [169] Multiple Sclerosis: 0.68 ± 0.32 pg/mL [153] Synovial fluid: 5 pmol/mL [173] Blister: 10–15 pg/mL [154] Sputum (Cystic Fibrosis): 200 pg/mL [174] Chronic Rhinosinusitis [155] COVID-19 and lung severity: Mild: 1.4 pg/mL [161] Severe: 1.0 pg/mL [161] Obesity (adiposity): Men: 7.4 pg/mL Women: 8.7 pg/mL [168] Salivary levels in periodontal and cardiovascular therapies: 0-6 months: 92.87–181.01 pg/mL [170] Pregnancy: First Trimester: 0.002 ± 0.001 [171] Second Trimester: 0.002 ± 0.001 [171] Third Trimester: 0.005 ± 0.011 [171]
Resolvin D2 (RvD2)	Nonobstructive coronary artery disease (WARRIOR Trial) [151] Metabolic Syndrome (weight loss program): 27 ± 2 pg/mL [150] Synovial fluid: 5 pmol/mL [173] Chronic Rhinosinusitis [155] COVID-19 and lung severity: Mild: 9.1 pg/mL [161] Moderate: 9.1 pg/mL [161] Severe: 5.1 pg/mL [161] Obesity (adiposity): Men: 6.4 pg/mL [168] Women: 6.6 pg/mL [168] Anetholea anisita extract for scalp condition [172]
Resolvin D3 (RvD3)	Human Vagus Nerve: 2.5 ± 0.7 pg/tissue [152] Nonobstructive coronary artery disease (WARRIOR Trial) [151] Stenotic Aortic Valves: 500–3500 pg/g tissue [149] Blister: 10–15 pg/mL [154] COVID-19 and lung severity: Mild: 1.5 pg/mL [161] Obesity (adiposity): Men: 5.2 pg/mL [168] Women: 5.1 pg/mL [168]
Resolvin D4 (RvD4)	Human Vagus Nerve: 0.9 ± 0.3 pg/tissue [152] Bone Marrow [175] COVID-19 and lung severity: Mild: 0.5 pg/mL [161]
Resolvin D5 (RvD5)	Human Vagus Nerve: 52.9 ± 20.2 pg/tissue [152] Nonobstructive coronary artery disease (WARRIOR Trial) [151] Plasma: 2–22 pg/mL [169] Multiple Sclerosis: 1.37 ± 0.43 pg/mL [153] Synovial fluid: 5 pmol/mL [173] COVID-19 and lung severity: Moderate: 15.0 pg/mL [161] Severe: 24.0 pg/mL [161] Obesity (adiposity): Men: 2.9 pg/mL [168] Women: 4.3 pg/mL [168]
Protectin/NeuroProtectin D1 (PD1/NPD1)	Human Vagus Nerve: 82.7 ± 33.5 pg/tissue [152] Multiple Sclerosis: 0.14 ± 0.03 pg/mL [153] Synovial fluid: 5 pmol/mL [173] Obesity (adiposity): Men: 32.5 pg/mL [168] Women: 48.6 pg/mL [168] Salivary levels in Periodontal and cardiovascular therapies: 0-6 months: 101.2–146.67 pg/mL [170]
Maresin 1 (MaR1)	Human Vagus Nerve: 6.9 ± 2.1 pg/tissue [152] Nonobstructive coronary artery disease (WARRIOR Trial) [151] Metabolic Syndrome (weight loss program): 35 ± 2 pg/mL [150] Synovial fluid: 5 pmol/mL [173] COVID-19 and lung severity: Mild: 36.7 pg/mL [161] Moderate: 40.9 pg/mL [161] Severe: 64.0 pg/mL [161] Obesity (adiposity): Men: 11.7 pg/mL [168] Women: 10.5 pg/mL [168] Salivary levels in Periodontal and cardiovascular therapies: 0-6 months: 125.51–337.03 [170] Pregnancy: First Trimester: 0.001 ± 0.001 [171] Second Trimester: 0.002 ± 0.001 [171] Third Trimester: 0.008 ± 0.020 [171]
Maresin 2 (MaR2)	COVID-19 and lung severity: Mild: 5.5 pg/mL [161] Moderate: 3.0 pg/mL [161] Severe: 14.5 pg/mL [161]